摘要：
Objective To observe the clinical efficacy of sodium ozagrel combined with Iow molecular weight heparin sodium and clopidogrel for progressive cerebral infarction,and to explore the best therapeutic regimen for this disorder.Methods 90 patients with progressive cerebral infarction were randomly divided into two groups,45 for each group.Both groups received conventional treatment for cerebral infarction and therapies for high blood pressure and diabetes mellitus.The study group received sodium ozagrel combined with low molecular weight heparin sodium and clopidogrel,while the conirol group was treated by acetylsalicylic acid alone for 15 days.The efficacy,Neurological Disability Scale ( NDS ),platelet count and coagulation function were eompared between the two groups after treatment.Results The total effectiveness rate differed significantly between the study group and the control group( 97.78％ vs.82.22％,P＜ 0.01 ).The score on NDS after treatment was markedly lower in the study group than in the control group [( 8.59 ± 5.17 ) vs.( 13.93 ± 4.05 ),P ＜ 0.01].The platelet count and the change in coagulation function were normal,with no significant statistical difference ( P ＞ 0.05 ).Conclusions Sodium ozagrel combined with low molecular weight heparin sodium and clopidogrel for progressive cerebral infarction has a synergetic effect and is safe.It effectively prevents infarction from deterioration,with better compliance and no adverse reactions,and is worth popu larizing clinically.%目的 观察奥扎格雷钠(晴尔)联合低分子肝素钠与氯吡格雷治疗进展性脑梗死的临床疗效,探讨进展性脑梗死的最佳治疗方案.方法 选择90例确诊为进展性脑梗死患者,并随机分为两组,各45例,两组均采用脑梗死常规治疗,并对伴发的高血压、糖尿病等进行对症治疗.观察组用晴尔联合低分子肝素钠与氯呲格雷治疗；对照组单用肠溶阿司匹林片治疗,均连续15d.比较两组疗效、治疗前后NDS评分、血小板计数及凝血功能变化.结果 观察组总有效率为97.78％,明显高于对照组(82.22％),两组相比较差异有显著性(P＜ 0.01)；治疗后观察组神经功能缺损评分(8.59±5.17)明显低于对照组的(13.93±4.05)(P＜0.01)；治疗后两组血小板计数及凝血功能均正常,差异无统计学意义(P＞ 0.05).结论 晴尔联合低分子肝索钠与氯吡格雷治疗进展性脑梗死具有协同且安全的作用,可有效地控制病情恶化,未发现不良反应,而且依从性好,是一种值得临床推广的治疗方案.
